Grand Pharmaceutical Group Ltd Announces Successful Phase II Clinical Study Results for STC3141

HONG KONG, May 7, 2025 /PRNewswire/ – Grand Pharmaceutical Group Limited (0512.HK, “Grand Pharma” or the “Group”), a leading international pharmaceutical company, has announced a significant milestone in its clinical research efforts. The company’s innovative drug, STC3141, has successfully reached the clinical endpoint in its Phase II clinical study for the treatment of sepsis in China.

Key Findings from the Study

The Phase II clinical study focused on evaluating the efficacy of STC3141, a groundbreaking sepsis treatment program designed to rebuild immune homeostasis. The results demonstrated that the SOFA (Sequential Organ Failure Assessment) scores of the drug treatment groups on the 7th day were significantly lower than those at baseline. Notably, the high-dose group exhibited a more substantial decrease in SOFA scores compared to the placebo group, with the differences being both statistically and clinically significant.

The study also found that the trend of the secondary endpoints was consistent with the primary endpoints, aligning with the initial expectations. This consistency underscores the potential of STC3141 as a transformative treatment option in the field of sepsis management.

Market and Financial Context

Grand Pharmaceutical Group Ltd, listed on the Hong Kong Stock Exchange, operates within the Health Care sector, specifically in the Pharmaceuticals industry. As of May 5, 2025, the company’s close price was HKD 5.99, with a market capitalization of HKD 21,160,000,000. The company’s price-to-earnings ratio stands at 8.46, reflecting its financial standing in the market.

Significance of the Achievement

STC3141 represents the first sepsis treatment program globally that centers on rebuilding immune homeostasis, marking a major advancement in the treatment dimension. This achievement positions Grand Pharma at the forefront of global pharmaceutical innovation, with the potential to significantly impact the management of sepsis worldwide.

The successful completion of this Phase II clinical study not only highlights Grand Pharma’s commitment to developing cutting-edge medical solutions but also sets the stage for further research and development efforts aimed at bringing STC3141 to patients in need.

For more information, please visit Grand Pharmaceutical Group Ltd’s official website .

Note: The information provided is based on the latest available data as of May 7, 2025.